RxDoctor Payments Data

Kinsman Wright, MD

Cardiovascular Disease · Chattanooga, TNNPI 1598764706

Payments from drug & device makers

$5,851in general payments, 2019–2025

Across 311 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$570
  • Pfizer$485
  • E.r. Squibb & Sons, L.L.C.$374
  • Amgen$352
  • Medtronic$312
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,67097%
  • Education$1813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,851 in reported general payments places this provider in the 65th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$93,571
Medicare patients
2,635
Services billed
4,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban125$150,065
EntrestoSacubitril/Valsartan92$111,069
EliquisApixaban127$107,955
Repatha SureclickEvolocumab113$83,503
FarxigaDapagliflozin Propanediol14$14,007
Ranolazine ErRanolazine53$7,054
Praluent PenAlirocumab12$6,218
Digoxin110$3,320
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$3,113
Flecainide Acetate51$2,900
Atorvastatin Calcium186$2,818
Rosuvastatin Calcium180$2,339
Carvedilol330$2,303
Losartan Potassium200$2,013
Valsartan27$1,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$570$150,065125 claims
NovartisEntresto$1,421$111,06992 claims
PfizerEliquis$485$107,955127 claims
AstraZenecaFarxiga$130$14,00714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →